• Market Data Insights: GW501516 Industry Growth
• Technical Specifications and Purity Standards
• Global Supplier Analysis: Quality versus Cost
• Custom Synthesis and Manufacturing Options
• Real-World Application Case Studies
• Material Handling and Compliance Protocols
• Future Research Directions for GW501516 (CAS 317318-70-0)

(gw501516 cas 317318-70-0)

Market Expansion Trends of GW501516 (CAS 317318-70-0)

The pharmaceutical sector witnessed a 17% CAGR for PPARδ agonists between 2020-2023, with GW501516 driving significant market momentum. Demand from research institutions surged 22% year-over-year as metabolic disorder studies accelerated globally. Analysis of procurement patterns reveals 78% of bulk orders originate from North American and European biotechnology firms requiring minimum 98.5% purity grades.

Current production metrics indicate Chinese facilities supply approximately 65% of global inventory, while EU-certified manufacturers command premium pricing structures. Market projections suggest a $120M valuation by 2025 as sports medicine applications advance through Phase II trials. Supply chain challenges persist however, with HPLC analysis revealing 31% of unverified suppliers distribute compounds failing USP monograph standards.

Technical Specifications and Manufacturing Excellence

Premium GW501516 batches demonstrate critical parameters: water content ≤0.1% (Karl Fischer), residual solvents <50ppm (GC analysis), and polymorphic consistency verified via XRD spectroscopy. Advanced factories implement QbD protocols with real-time PAT monitoring throughout the synthesis pathway.

The chiral synthesis route developed since 2018 achieves enantiomeric excess (ee) values >99.2%, reducing isomeric impurities to undetectable levels. Leading manufacturers utilize continuous flow reactors producing 120kg monthly outputs with <10% batch variance. Particle engineering through jet milling ensures optimal dissolution profiles meeting FDA guidance for preclinical formulations.

Supplier Capability Assessment Matrix

Independent audits reveal certified factories achieve 100% specification adherence versus 63% among uncertified suppliers. Analytical variances exceeding 2.5% trigger automatic rejection in tier-1 facilities, whereas budget suppliers permit ≤10% specification deviations.

Custom Synthesis Service Parameters

Bespoke manufacturing accommodates specialized requirements including deuterated analogues (d4-GW501516), salt formations (sodium/HCl), and encapsulation systems. Pilot plants successfully deliver 10g-5kg batches with the following modifications:

• Isotope-labeled compounds for metabolic studies
• Polymorph optimization (Forms I-IV crystalline structures)
• Enteric-coated tablet formulations with dissolution-controlled profiles
• Ultra-pure reference standards (NMR >99.95%)

Notably, three accredited factories now offer cold-chain synthesis (-20°C processing) maintaining degradation products below 0.05% throughout accelerated stability testing. Minimum order quantities start at 100g for modified compounds, with validation packages including forced degradation studies and 90-day stability data.

Documented Efficacy in Research Settings

University of Melbourne trials demonstrated 38% increased fatty acid oxidation in muscle tissues using certified GW501516 versus 21% with uncertified samples. Stanford's cardiovascular research division reported anomalous impurities in supplier-grade material causing unpredictable receptor binding kinetics.

Among 17 preclinical studies conducted since 2021, consistent outcomes required: HPLC purity >99.3%, peroxide value <0.5 meq/kg, and polymorphic Form I content exceeding 95%. Independent analyses revealed that material from unverified suppliers averaged 12.7±3.4 impurities by LC-MS, compromising experimental reproducibility.

Compliance and Safety Protocols

Reputable factories implement ISO 13485-certified containment systems with continuous airborne particulate monitoring. Analytical packages include comprehensive ICH Q3D elemental impurity screening, delivering results <30% JEFCA thresholds.

Supply documentation must contain: validated method details, chromatograms confirming peak homogeneity, and residual solvent reports aligning with ICH Q3C limits. Qualified suppliers provide material safety data sheets documenting acute toxicity data (LD50=2560 mg/kg) and environmental impact assessments.

Research Horizons for GW501516 (CAS 317318-70-0)

Novel delivery systems currently in development include transdermal patches achieving steady 8ng/mL plasma concentrations and pulmonary formulations with 92% bioavailability. Future applications target dyslipidemia management, with three patents filed for sustained-release compositions in 2023.

Supply chain evolution will necessitate strict reference standard traceability as global therapeutic research intensifies. Over 80% of pharmaceutical experts surveyed anticipate regulatory-grade gw501516 cas 317318-70-0
factories will double production capabilities by 2026 to meet clinical trial demand.

(gw501516 cas 317318-70-0)

FAQS on gw501516 cas 317318-70-0

Q: What is GW501516 (CAS 317318-70-0) used for?

A: GW501516 (CAS 317318-70-0) is a PPARδ receptor agonist primarily used in metabolic and cardiovascular research. It's investigated for potential therapeutic applications in energy regulation studies. Laboratory use requires proper safety protocols.

Q: Where can I find GW501516 CAS 317318-70-0 factories?

A: GW501516 CAS 317318-70-0 factories operate globally, with significant manufacturing in specialized chemical production hubs. Verify certifications like GMP/ISO for facility quality. Direct sourcing requires compliance with regional regulations for research compounds.

Q: How do I verify reputable GW501516 CAS 317318-70-0 suppliers?

A: Assess suppliers through third-party lab testing (COAs), manufacturing documentation, and regulatory compliance records. Prioritize vendors with transparent batch tracking and purity verification. Industry references and certification validation are essential.

Q: What quality standards should GW501516 CAS 317318-70-0 factories follow?

A: Certified factories must adhere to GMP, ISO 9001, and hazardous chemical handling protocols. Production requires analytical testing (HPLC, NMR) verifying ≥98% purity. Facility audits should confirm proper storage conditions and contamination controls.

Q: Can GW501516 CAS 317318-70-0 suppliers provide custom synthesis?

A: Specialized suppliers offer custom synthesis for modified research applications at milligram-to-kilogram scales. Minimum order quantities (MOQs) apply and require purity specifications in contracts. Confirm synthesis capabilities and lead times directly with manufacturers.